Boston Scientific Corporation
BSXHealthcareNASDAQMedical Devices · Last scanned May 30, 2026
Scan Results
Daily timeframeBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The $71.81B market capitalization puts BSX squarely in large-cap range for its industry. The company operates in two segments, MedSurg and Cardiovascular.
Market Cap
$71.81B
Beta
0.62
P/E (TTM)
20.21
P/E (Fwd)
12.92
EPS (TTM)
$2.39
EPS (Fwd)
$3.74
ROE
14.7%
ROA
6.1%
Cash
$1.45B
Total Debt
$11.03B
Free CF
$2.81B
52W Change
-53.6%
Annual Financials
Cash vs Debt
Boston Scientific Corporation carries $11.03B in total debt against $1.45B in cash reserves — debt is roughly 7.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $2.81B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 14.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $12.68B (2022) to $20.07B (2025), reflecting a 58% increase over the period.
The relatively low beta of 0.62 suggests BSX is a less volatile holding compared to the broader index. Boston Scientific Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Boston Scientific Corporation's trajectory.